3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
CNS
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
21
Capecitabine
19
Fluorouracil
16
Bevacizumab
16
Esomeprazole
11
Sorafenib
10
Irinotecan
9
Leucovorin
8
Radiofrequency Ablation
7
Propofol
7
Bismuth
7
Morphine
6
Gemcitabine
6
Folfox protocol
6
Amoxicillin
6
lenvatinib
5
gadolinium ethoxybenzyl DTPA
5
Tetracycline
5
Sevoflurane
5
S 1 (combination)
5
Drug Therapy
5
Control Groups
5
Cisplatin
5
sodium glycididazole
4
fish oil triglycerides
4
ferric carboxymaltose
4
Sodium Chloride
4
Ropivacaine
4
Ribavirin
4
Hepatectomy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
gadoterate meglumine
×
Gastrointestinal
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled
NCT01806740
2019-08-08
DCE-MRI
Guerbet
Phase 4
Terminated
37 enrolled
12 charts